

Date: 11th August, 2026

To,
The Manager,
Department of Corporate Services,
BSE Limited
1st Floor, Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001
Scrip Code: 506235

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza"
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE Symbol: ALEMBICLTD

Dear Sir,

Sub: Outcome of Board Meeting

With reference to the captioned subject, the exchanges are hereby informed that the Board of Directors of Alembic Limited at its meeting held today has *inter alia* approved the Unaudited Financial Results of the Company for the quarter ended 30th June, 2026:

We enclose herewith the following:

- Consolidated Unaudited Financial Results for the quarter ended 30th June, 2026.
- Standalone Unaudited Financial Results for the quarter ended 30th June, 2026.
- Limited Review Report by Statutory Auditors on the Consolidated and Standalone Unaudited Financial Results.

The time of commencement of the Board Meeting was 3:30 p.m. and the time of conclusion was 4:00 p.m.


We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Limited


Keval Thakkar
Company Secretary



Encl.: A/a

ALEMBIC LIMITED



ALEMBIC LIMITED
CIN:L26100GJ1907PLC000033
Regd. Office: Alembic Road, Vadodara 390 003
Ph:0265 6637000
www.alembiclimited.com Email:alembic.investors@alembic.co.in

Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2026

Sr. No	Particulars	Quarter Ended			Rs. in Lakhs
		30.06.2026 (Unaudited)	31.03.2026 (Audited)	30.06.2025 (Unaudited)	31.03.2026 (Audited)
1	Revenue from Operations	4,874	6,004	4,975	23,999
2	Other Income	596	214	359	7,297
3	Total Income	5,471	6,218	5,334	31,296
4	Expenses				
	Cost of Materials Consumed	493	404	345	1,388
	Cost of Construction	862	1,463	1,010	6,002
	Changes in Inventories of Finished Goods and WIP	(51)	(65)	174	255
	Employee Benefit Expenses	1,046	1,174	783	3,744
	Finance Costs	60	57	59	228
	Depreciation and amortisation expense	348	334	279	1,239
	Other Expenses	979	1,006	705	3,564
	Total Expenses	3,737	4,374	3,356	16,420
5	Profit Before Tax (3-4)	1,734	1,844	1,978	14,876
6	Tax Expenses				
	Current Tax	193	566	202	2,263
	Deferred Tax	(29)	287	(3)	(10)
	Short / (Excess) Provision of earlier years	-	30	-	30
7	Net Profit after tax for the Period	1,570	961	1,780	12,593
8	Share of Associate's Profit/(Loss)	4,919	5,752	4,384	19,145
9	Net Profit/(Loss) after tax and Share of Associate's Profit/(Loss)	6,489	6,713	6,164	31,738
10	Other Comprehensive Income				
	A (i) Items that will not be reclassified to Profit or (Loss)	7,048	(11,724)	482	(10,562)
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	(752)	1,241	(69)	925
	B (i) Items that will be reclassified to Profit or (Loss)	90	384	31	882
	(ii) Income tax relating to items that will be reclassified to Profit or Loss	(14)	-	-	-
11	Total Comprehensive Income/(Loss) for the Period	12,860	(3,387)	6,609	22,983
12	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
13	Other Equity (excluding Revaluation Reserve)				2,24,927
14	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	2.53	2.61	2.40	12.36



Alembic Limited

Segment wise Consolidated Revenue and Results

Sr. No	Particulars	Quarter Ended		Rs. In Lakhs	
		30.06.2026 (Unaudited)	31.03.2026 (Audited)	30.06.2025 (Unaudited)	31.03.2026 (Audited)
1	Segment Revenue				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	1,171	983	1,295	4,659
	b. Real Estate Business	3,703	5,021	3,680	19,340
	Total Income from Operations (Net)	4,874	6,004	4,975	23,999
2	Segment Results (Profit (+)/ Loss (-) before Taxes and Interest from each segment)				
	a. Active Pharmaceutical Ingredients Business	166	(117)	273	565
	b. Real Estate Business	1,398	2,097	1,594	8,117
	Total	1,564	1,980	1,867	8,682
	Unallocable Income and Expenditure				
	(i) Interest Expense	(60)	(57)	(59)	(228)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	220	(121)	171	6,167
	(iii) Other Income / (Expense)	11	42	0	255
	Total Profit Before Tax	1,734	1,844	1,978	14,876
3	Segment Assets				
	a. Active Pharmaceutical Ingredients Business	18,228	18,081	19,170	18,081
	b. Real Estate Business	52,873	51,578	46,822	51,578
	c. Unallocated	2,00,856	1,89,291	1,86,165	1,89,291
	Total	2,71,957	2,58,951	2,52,158	2,58,951
4	Segment Liabilities				
	a. Active Pharmaceutical Ingredients Business	3,577	3,480	3,647	3,480
	b. Real Estate Business	7,765	8,148	10,857	8,148
	c. Unallocated	3,247	2,814	3,356	2,814
	Total	14,588	14,442	17,861	14,442

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- The figures for the quarter ended 31st March, 2026 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2026 and year to date unaudited figures upto third quarter ended 31st December, 2025.

Place : Vadodara
Date : 11th August, 2026



For Alembic Limited


Udit Amin
Managing Director



ALEMBIC LIMITED
CIN:L26100GJ1907PLC000033
Regd. Office: Alembic Road, Vadodara 390 003
Ph:0265 6637000
www.alembiclimited.com Email:alembic.investors@alembic.co.in

Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2026

Sr. No.	Particulars	Quarter Ended			Rs. in Lakhs
		30.6.2026 (Unaudited)	31.3.2026 (Audited)	30.06.2025 (Unaudited)	31.03.2026 (Audited)
1	Revenue from Operations	4,627	5,773	4,789	23,193
2	Other Income	555	241	346	7,277
3	Total Income	5,182	6,014	5,134	30,470
4	Expenses				
	Cost of Materials Consumed	493	404	345	1,388
	Cost of Construction	862	1,463	1,010	6,002
	Changes in Inventories of Finished Goods and WIP	(51)	(65)	174	255
	Employee Benefit Expenses	1,046	1,174	783	3,744
	Finance Costs	37	37	42	157
	Depreciation and amortisation expense	338	325	270	1,201
	Other Expenses	873	841	619	3,035
	Total Expenses	3,598	4,180	3,243	15,781
5	Profit Before Tax (3-4)	1,584	1,834	1,892	14,689
6	Tax Expenses				
	Current Tax	159	550	180	2,200
	Deferred Tax	(44)	301	(0)	5
	Short / (Excess) Provision of earlier years	-	30	-	30
7	Net Profit after tax for the Period	1,468	953	1,712	12,454
8	Other Comprehensive Income				
	(i) Items that will not be reclassified to Profit or (Loss)	7,062	(11,668)	495	(10,363)
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	(756)	1,240	(71)	898
9	Total Comprehensive Income/(Loss) for the Period	7,774	(9,476)	2,136	2,989
10	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
11	Other Equity (excluding Revaluation Reserve)				62,564
12	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	0.57	0.37	0.67	4.85



Alembic Limited

Segment wise Standalone Revenue and Results

Sr. No.	Particulars	Quarter Ended			Rs. in Lakhs
		30.06.2026 (Unaudited)	31.3.2026 (Audited)	30.06.2025 (Unaudited)	31.03.2026 (Audited)
1	Segment Revenue				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	1,171	983	1,295	4,659
	b. Real Estate Business	3,455	4,790	3,493	18,535
	Total Income from Operations (Net)	4,627	5,773	4,789	23,193
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)				
	a. Active Pharmaceutical Ingredients Business	166	(117)	273	565
	b. Real Estate Business	1,224	2,067	1,490	7,859
	Total	1,391	1,950	1,763	8,424
	Unallocable Income and Expenditure				
	(i) Interest Expense	(37)	(37)	(42)	(157)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	220	(121)	171	6,167
	(iii) Other Income / (Expense)	11	42	0	255
	Total Profit Before Tax	1,584	1,834	1,892	14,689
3	Segment Assets				
	a. Active Pharmaceutical Ingredients Business	18,228	18,081	19,170	18,081
	b. Real Estate Business	51,262	50,165	45,574	50,165
	c. Unallocated	34,104	27,524	39,847	27,524
	Total	1,03,594	95,770	1,04,591	95,770
4	Segment Liabilities				
	a. Active Pharmaceutical Ingredients Business	3,577	3,480	3,647	3,480
	b. Real Estate Business	6,707	7,190	9,944	7,190
	c. Unallocated	3,390	2,954	3,545	2,954
	Total	13,674	13,625	17,136	13,625

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- The figures for the quarter ended 31st March, 2026 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2026 and year to date unaudited figures upto third quarter ended 31st December, 2025.

Place : Vadodara
Date : 11th August, 2026



For Alembic Limited

Udit Amin
Managing Director

CNK & Associates LLP

Chartered Accountants

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alembic Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2026 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable.

4. Emphasis of Matter

We draw attention to the status of disputed liability related to pending electricity duty matter. During the previous periods, the Company had made aggregate provision towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability in the Consolidated Financial Statements for the year ended 31st March, 2026. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26th May, 2023 and the appeal filed by the Company has been admitted.

Our opinion is not modified in respect of above matter.




The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: www.cnkindia.com


5. The statement includes results of the following entities:
- Alembic City Limited (Subsidiary)
 - Alembic Pharmaceuticals Limited (Associate)
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose financial results reflect total revenue of Rs.1,241.62 lakhs, total net Profit/(Loss) after tax of Rs.(14.26) lakhs and total comprehensive income/(Loss) of Rs. (14.02) lakhs for the quarter ended 30th June, 2026. The unaudited consolidated financial results also include the Group's share of net profit after tax of Rs.4,919.02 lakhs and total comprehensive income of Rs. 4,984.09 lakhs for the quarter ended 30th June, 2026, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For C N K & Associates LLP
Chartered Accountants
Firm Registration No. 101961W/W-100036


Rachit Sheth
Partner

Membership No.158289
Place: Vadodara
Date: 11th August, 2026
UDIN: 26158289TTZWDT3534



Independent Auditor's Review Report on Unaudited Standalone Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of Alembic Limited ("the Company") for the quarter ended 30th June, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: www.cnkindia.com

VADODARA | MUMBAI | CHENNAI | AHMEDABAD | GIFT CITY | GURGOON | KOLKATA | BENGALURU | DELHI | PUNE | DUBAI | ABU DHABI

4. Emphasis of Matter

We draw attention to the status of disputed liability related to pending electricity duty matter. During the previous periods, the Company had made aggregate provision towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability in the Standalone Financial Statements for the year ended 31st March, 2026. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26th May, 2023 and the appeal filed by the Company has been admitted.


Our opinion is not modified in respect of above matter.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For C N K & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036



Rachit Sheth

Partner

Membership No.158289

Place: Vadodara

Date:11th August 2026

UDIN: 26158289BRLQIR2911

